Aligos Therapeutics, Inc. (ALGS)
 NASDAQ: ALGS · Real-Time Price · USD
 8.20
 -0.41 (-4.76%)
  Oct 30, 2025, 4:00 PM EDT - Market closed
Aligos Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
 Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 | 
|---|---|---|---|---|---|---|---|
| Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 | 
| Cash & Equivalents | 18.66 | 37 | 135.7 | 81.35 | 186.82 | 220.38 | Upgrade  | 
| Short-Term Investments | 104.28 | 19.94 | - | 44.48 | 3.92 | 23.13 | Upgrade  | 
| Cash & Short-Term Investments | 122.95 | 56.94 | 135.7 | 125.83 | 190.73 | 243.51 | Upgrade  | 
| Cash Growth | 30.05% | -58.04% | 7.85% | -34.03% | -21.67% | 106.96% | Upgrade  | 
| Restricted Cash | 0.11 | 0.11 | 0.07 | 0.12 | 0.16 | 0.56 | Upgrade  | 
| Other Current Assets | 4.89 | 5.09 | 5.31 | 7.6 | 13.53 | 5.94 | Upgrade  | 
| Total Current Assets | 127.94 | 62.14 | 141.08 | 133.55 | 204.42 | 250.02 | Upgrade  | 
| Property, Plant & Equipment | 6.12 | 7.33 | 9.82 | 12.51 | 14.97 | 14.91 | Upgrade  | 
| Long-Term Investments | - | - | - | - | 15.11 | - | Upgrade  | 
| Other Long-Term Assets | 0.64 | 0.63 | 0.63 | 0.63 | 0.87 | 0.38 | Upgrade  | 
| Total Assets | 134.71 | 70.09 | 151.53 | 146.69 | 235.37 | 265.3 | Upgrade  | 
| Accounts Payable | 3.94 | 2.57 | 2.52 | 4.74 | 3.02 | 3.31 | Upgrade  | 
| Accrued Expenses | 12.21 | 15.56 | 16.84 | 16.04 | 25.39 | 16.56 | Upgrade  | 
| Current Portion of Leases | 3.54 | 3.46 | 3.24 | 3.14 | 2.91 | 2.51 | Upgrade  | 
| Current Unearned Revenue | 0.58 | 0.15 | 1.31 | 9.21 | 7.64 | 7.89 | Upgrade  | 
| Total Current Liabilities | 20.27 | 21.74 | 23.91 | 33.13 | 38.96 | 30.27 | Upgrade  | 
| Long-Term Leases | 3.34 | 4.92 | 7.9 | 9.43 | 11.55 | 10.5 | Upgrade  | 
| Long-Term Unearned Revenue | - | - | - | 0.23 | - | 4.11 | Upgrade  | 
| Other Long-Term Liabilities | 9.24 | 72.41 | 27.64 | - | 0.13 | 0.38 | Upgrade  | 
| Total Liabilities | 32.84 | 99.07 | 59.45 | 42.79 | 50.64 | 45.26 | Upgrade  | 
| Common Stock | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 | Upgrade  | 
| Additional Paid-In Capital | 692.22 | 588.58 | 578.33 | 502.61 | 487.35 | 394.96 | Upgrade  | 
| Retained Earnings | -590.78 | -618.01 | -486.8 | -399.12 | -303.07 | -174.74 | Upgrade  | 
| Comprehensive Income & Other | 0.42 | 0.45 | 0.55 | 0.4 | 0.45 | -0.19 | Upgrade  | 
| Total Common Equity | 101.87 | -28.97 | 92.08 | 103.9 | 184.73 | 220.04 | Upgrade  | 
| Shareholders' Equity | 101.87 | -28.97 | 92.08 | 103.9 | 184.73 | 220.04 | Upgrade  | 
| Total Liabilities & Equity | 134.71 | 70.09 | 151.53 | 146.69 | 235.37 | 265.3 | Upgrade  | 
| Total Debt | 6.88 | 8.38 | 11.14 | 12.57 | 14.46 | 13.01 | Upgrade  | 
| Net Cash (Debt) | 116.07 | 48.56 | 124.57 | 113.25 | 176.28 | 230.51 | Upgrade  | 
| Net Cash Growth | 37.04% | -61.01% | 9.99% | -35.75% | -23.52% | 123.07% | Upgrade  | 
| Net Cash Per Share | 14.82 | 7.75 | 48.59 | 66.31 | 110.57 | 576.95 | Upgrade  | 
| Filing Date Shares Outstanding | 6.15 | 6.11 | 3.03 | 1.72 | 1.71 | 1.53 | Upgrade  | 
| Total Common Shares Outstanding | 6.15 | 3.86 | 3 | 1.72 | 1.71 | 1.52 | Upgrade  | 
| Working Capital | 107.68 | 40.4 | 117.18 | 100.42 | 165.47 | 219.74 | Upgrade  | 
| Book Value Per Share | 16.56 | -7.50 | 30.65 | 60.52 | 108.18 | 144.30 | Upgrade  | 
| Tangible Book Value | 101.87 | -28.97 | 92.08 | 103.9 | 184.73 | 220.04 | Upgrade  | 
| Tangible Book Value Per Share | 16.56 | -7.50 | 30.65 | 60.52 | 108.18 | 144.30 | Upgrade  | 
| Machinery | 8.19 | 8.04 | 7.91 | 8.28 | 7.48 | 6.23 | Upgrade  | 
| Construction In Progress | 0 | 0 | 0 | 0.02 | 0.02 | 0.07 | Upgrade  | 
| Leasehold Improvements | 6.1 | 6.1 | 6.1 | 6.09 | 5.94 | 5.66 | Upgrade  | 
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.